Regeneron Pharmaceuticals Statistics

Total Valuation

LON:0R2M has a market cap or net worth of GBP 42.91 billion. The enterprise value is 31.99 billion.

Market Cap	42.91B
Enterprise Value	31.99B

Important Dates

The last earnings date was Friday, August 1, 2025.

Earnings Date	Aug 1, 2025
Ex-Dividend Date	May 20, 2025

Share Statistics

Current Share Class	101.87M
Shares Outstanding	n/a
Shares Change (YoY)	-1.75%
Shares Change (QoQ)	-2.34%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	97.91M

Valuation Ratios

The trailing PE ratio is 13.19 and the forward PE ratio is 13.21.

PE Ratio	13.19
Forward PE	13.21
PS Ratio	4.14
PB Ratio	1.96
P/TBV Ratio	2.06
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.64, with an EV/FCF ratio of 11.37.

EV / Earnings	9.83
EV / Sales	3.05
EV / EBITDA	9.64
EV / EBIT	10.97
EV / FCF	11.37

Financial Position

The company has a current ratio of 4.60, with a Debt / Equity ratio of 0.09.

Current Ratio	4.60
Quick Ratio	3.57
Debt / Equity	0.09
Debt / EBITDA	0.60
Debt / FCF	0.70
Interest Coverage	108.11

Financial Efficiency

Return on equity (ROE) is 15.34% and return on invested capital (ROIC) is 7.78%.

Return on Equity (ROE)	15.34%
Return on Assets (ROA)	6.66%
Return on Invested Capital (ROIC)	7.78%
Return on Capital Employed (ROCE)	11.45%
Revenue Per Employee	683,371
Profits Per Employee	214,355
Employee Count	15,106
Asset Turnover	0.38
Inventory Turnover	2.46

Taxes

In the past 12 months, LON:0R2M has paid 303.78 million in taxes.

Income Tax	303.78M
Effective Tax Rate	8.54%

Stock Price Statistics

The stock price has decreased by -50.30% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-50.30%
50-Day Moving Average	539.83
200-Day Moving Average	651.34
Relative Strength Index (RSI)	51.25
Average Volume (20 Days)	3,159

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.94

Income Statement

In the last 12 months, LON:0R2M had revenue of GBP 10.37 billion and earned 3.25 billion in profits. Earnings per share was 28.96.

Revenue	10.37B
Gross Profit	4.91B
Operating Income	2.89B
Pretax Income	3.56B
Net Income	3.25B
EBITDA	3.26B
EBIT	2.89B
Earnings Per Share (EPS)	28.96

Full Income Statement

Balance Sheet

The company has 5.45 billion in cash and 1.97 billion in debt, giving a net cash position of 10.82 billion.

Cash & Cash Equivalents	5.45B
Total Debt	1.97B
Net Cash	10.82B
Net Cash Per Share	n/a
Equity (Book Value)	21.85B
Book Value Per Share	209.88
Working Capital	9.63B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.46 billion and capital expenditures -649.47 million, giving a free cash flow of 2.81 billion.

Operating Cash Flow	3.46B
Capital Expenditures	-649.47M
Free Cash Flow	2.81B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 47.35%, with operating and profit margins of 27.84% and 31.37%.

Gross Margin	47.35%
Operating Margin	27.84%
Pretax Margin	34.30%
Profit Margin	31.37%
EBITDA Margin	31.42%
EBIT Margin	27.84%
FCF Margin	27.11%

Dividends & Yields

This stock pays an annual dividend of 1.35, which amounts to a dividend yield of 0.24%.

Dividend Per Share	1.35
Dividend Yield	0.24%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	4.18%
Buyback Yield	1.75%
Shareholder Yield	1.99%
Earnings Yield	7.58%
FCF Yield	6.56%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0R2M has an Altman Z-Score of 8.61 and a Piotroski F-Score of 4.

Altman Z-Score	8.61
Piotroski F-Score	4